PDS Biotechnology Corporation (PDSB) is up 30.1% today. Here is some analysis on what might have caused this price movement.
Analysis: The sharp move appears tied to PDS Biotech’s announcement of up to $22.55 million in PIPE financing led by Nant Capital, alongside board involvement from Dr. Patrick Soon-Shiong and a plan to push PDS0301 toward late-stage development. For a small clinical-stage biotech that recently reported limited cash, investors likely viewed the financing as both a balance-sheet lifeline and a strategic endorsement.
Details:
Sources:
SEC, PDS Biotech, Yahoo Finance
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$PDSB Hedge Fund Activity
We have seen 26 institutional investors add shares of $PDSB stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FOCUS PARTNERS WEALTH added 642,177 shares (+inf%) to their portfolio in Q2 2026, for an estimated $565,822
- QUANTINNO CAPITAL MANAGEMENT LP added 642,177 shares (+inf%) to their portfolio in Q2 2026, for an estimated $565,822
- MILITIA CAPITAL MANAGEMENT LLC added 331,800 shares (+inf%) to their portfolio in Q2 2026, for an estimated $292,348
- MORGAN STANLEY added 310,000 shares (+7904.1%) to their portfolio in Q2 2026, for an estimated $273,141
- JANE STREET GROUP, LLC added 279,664 shares (+inf%) to their portfolio in Q2 2026, for an estimated $246,411
- SQUAREPOINT OPS LLC removed 192,556 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $116,496
- ARMISTICE CAPITAL, LLC removed 173,605 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $152,963
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.